Denali Therapeutics Inc. 8-K

What Happened

• Denali Therapeutics, Inc. announced its financial results for the fourth quarter ended December 31, 2025. The company issued a press release on February 26, 2026 (attached as Exhibit 99.1 to the Form 8-K) reporting its quarterly results and financial condition. The press release is furnished with the Form 8‑K and incorporated by reference in the filing.

Key Details

• Date of filing/announcement: February 26, 2026.
• Reporting period: Quarter ended December 31, 2025 (Q4 2025).
• Press release attached as Exhibit 99.1 and furnished with the Form 8‑K.
• The information furnished (including Exhibit 99.1) is explicitly noted as not being “filed” for purposes of Section 18 of the Exchange Act and will not be incorporated by reference into other registration statements or filings under the Securities Act or Exchange Act unless specifically stated.

Why It Matters

• This 8‑K provides Denali’s latest quarterly results and updates on its financial condition—information investors use to assess near‑term performance and valuation.
• Because the press release is furnished (not “filed”), investors should review the full Exhibit 99.1 and any subsequently filed quarterly or annual reports for audited and detailed financial statements and management discussion.